Compare BIO-TECHNE Corp (TECH) vs Upwork Inc (UPWK) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
BIO-TECHNE Corp vs Upwork Inc — how do they compare? BIO-TECHNE Corp trades at $72.39 (market cap $11.34B), while Upwork Inc trades at $8.31 (market cap $1.04B). The key difference: BIO-TECHNE Corp is far larger — about 10.9× Upwork Inc's market cap, and BIO-TECHNE Corp pays a 0.44% dividend while Upwork Inc pays none. Which is the better fit depends on your goals.
| TECH | UPWK | |
|---|---|---|
Market Cap | $11.34B | $1.04B |
Sector | Health | Industrials |
52-Week High | $72.48 | $22.11 |
52-Week Low | $43.31 | $7.84 |
Enterprise Value | $11.36B | $802.40M |
Dividend Yield | 0.44% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Bio-Techne (TECH) trades at $72.31, down 0.17% on the day, with a neutral technical signal and mixed earnings history. The stock is near the consensus price target of $71.86, with a pending acquisition by Merck KGaA at $73.00 per share. Recent Q4 2026 revenue beat estimates, but net income margin compression from 25.09% in 2023 to 14.96% in 2026 highlights profitability challenges. Operating cash flow remains stable around $290M, supporting dividend payments.
The outlook is balanced, with upside capped by the acquisition offer but supported by solid cash flow and analyst hold ratings. Risks include shareholder litigation and integration uncertainties post-acquisition. Earnings growth in diagnostics and spatial biology segments is a key catalyst, though high P/E of 62.33 suggests elevated expectations.
Upwork (UPWK) is trading at $8.32, down 5.35% on the day, with a bearish technical signal and recent earnings volatility. The company maintains strong profitability metrics including a 77.21% gross margin and 12.93% net income margin, though Q2 2026 earnings beat was overshadowed by weak guidance. Recent news highlights multiple securities fraud investigations alongside AI integration developments.
The stock presents a mixed outlook with attractive valuation multiples (P/E 10.67, P/S 1.44) but faces headwinds from AI disruption and legal scrutiny. Analyst consensus leans bullish with a $9.00 price target, though technical indicators suggest near-term pressure with support at $8.00.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About BIO-TECHNE Corp
Based in Minnesota, Bio-Techne is a life sciences manufacturer supplying consumables and instruments for the pharma, biotech, academic, and diagnostic markets. The company reports in two segments, protein sciences (75% of revenue), and diagnostics and genomics (25%). The protein-focused segment makes equipment and associated consumables for protein characterization and analysis and sells antibodies for research and clinical purposes. In diagnostics, Bio-Techne provides controls and calibrators for diagnostic manufacturers and has a portfolio of diagnostic oncology assays. The United States accounts for about 55% of revenue, and the firm also has operations in EMEA (20% of sales), the U.K. (5%), and APAC (15%), with the rest of the world accounting for the remaining 5%.
Read more on TECH →About Upwork Inc
Upwork Inc is a United States-based company that operates an online marketplace that enables businesses to find and work with highly-skilled independent professionals. The develops platform for hiring and freelancing purposes. Its products offering include Upwork Basic, Upwork Plus, Upwork Business, Upwork Enterprise, and Upwork Payroll. The business generates revenue from Talent and Clients across the USA, India, the Philippines and the rest of the world. Substantial income is derived from providing services to Clients.
Read more on UPWK →
